Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?
OncoReview · 2017
DOI: 10.24292/01.or.211217 ↗Kurz gefasst
Fachartikel in der Zeitschrift OncoReview, 2017. Verfasst von Przemysław Witek und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Cushing’s disease is a rare endocrine disorder caused by ACTH-secreting pituitary adenoma. The treatment of choice is a transsphenoidal surgery performed by an experienced neurosurgeon. However, in some patients adjuvant treatment is required due to ineffective surgery or disease recurrence. This article discusses new aspects of pharmacological treatment of ACTH-dependent hypercortisolism in light of a recent publication reporting the efficacy and safety of once a month pasireotide LAR injections in Cushing’s disease
Zitieren
APA
Witek, P., Mazur, M., & Witek, J. (2017). Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?. OncoReview. https://doi.org/10.24292/01.or.211217
Vancouver
Witek P, Mazur M, Witek J. Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?. OncoReview. 2017. doi:10.24292/01.or.211217
BibTeX
@article{Witek2017,
author = {Witek, Przemysław and Mazur, Marta and Witek, Joanna},
title = {Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?},
journal = {OncoReview},
year = {2017},
doi = {10.24292/01.or.211217}
}
EUVIMED